Richard W Tsang1, Belinda A Campbell2, Jayant S Goda3, Chris R Kelsey4, Youlia M Kirova5, Rahul R Parikh6, Andrea K Ng7, Umberto Ricardi8, Chang-Ok Suh9, Peter M Mauch7, Lena Specht10, Joachim Yahalom11. 1. Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. Electronic address: richard.tsang@rmp.uhn.on.ca. 2. Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 3. Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India. 4. Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. 5. Department of Radiation Therapy, Institut Curie, Paris, France. 6. Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey. 7. Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts. 8. Radiation Oncology Unit, Department of Oncology, University of Torino, Torino, Italy. 9. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, South Korea. 10. Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 11. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Abstract
PURPOSE: To develop guidelines for the work-up and radiation therapy (RT) management of patients with plasma cell neoplasms. METHODS AND MATERIALS: A literature review was conducted covering staging, work-up, and RT management of plasma cell neoplasms. Guidelines were developed through consensus by an international panel of radiation oncologists with expertise in these diseases, from the International Lymphoma Radiation Oncology Group. RT volume definitions are based on the International Commission on Radiation Units and Measurements. RESULTS: Plasma cell neoplasms account for approximately one-fifth of mature B-cell neoplasms in the United States. The majority (∼95%) are diagnosed as multiple myeloma, in which there has been tremendous progress in systemic therapy approaches with novel drugs over the last 2 decades, resulting in improvements in disease control and survival. In contrast, a small proportion of patients with plasma cell neoplasms present with a localized plasmacytoma in the bone, or in extramedullary (extraosseous) soft tissues, and definitive RT is the standard treatment. RT provides long-term local control in the solitary bone plasmacytomas and is potentially curative in the extramedullary cases. This guideline reviews the diagnostic work-up, principles, and indications for RT, target volume definition, treatment planning, and follow-up procedures for solitary plasmacytoma. Specifically, detailed recommendations for RT volumes and dose/fractionation are provided, illustrated with specific case scenarios. The role of palliative RT in multiple myeloma is also discussed. CONCLUSIONS: The International Lymphoma Radiation Oncology Group presents a standardized approach to the use and implementation of definitive RT in solitary plasmacytomas. The modern principles outlining the supportive role of palliative RT in multiple myeloma in an era of novel systemic therapies are also discussed. Crown
PURPOSE: To develop guidelines for the work-up and radiation therapy (RT) management of patients with plasma cell neoplasms. METHODS AND MATERIALS: A literature review was conducted covering staging, work-up, and RT management of plasma cell neoplasms. Guidelines were developed through consensus by an international panel of radiation oncologists with expertise in these diseases, from the International Lymphoma Radiation Oncology Group. RT volume definitions are based on the International Commission on Radiation Units and Measurements. RESULTS: Plasma cell neoplasms account for approximately one-fifth of mature B-cell neoplasms in the United States. The majority (∼95%) are diagnosed as multiple myeloma, in which there has been tremendous progress in systemic therapy approaches with novel drugs over the last 2 decades, resulting in improvements in disease control and survival. In contrast, a small proportion of patients with plasma cell neoplasms present with a localized plasmacytoma in the bone, or in extramedullary (extraosseous) soft tissues, and definitive RT is the standard treatment. RT provides long-term local control in the solitary bone plasmacytomas and is potentially curative in the extramedullary cases. This guideline reviews the diagnostic work-up, principles, and indications for RT, target volume definition, treatment planning, and follow-up procedures for solitary plasmacytoma. Specifically, detailed recommendations for RT volumes and dose/fractionation are provided, illustrated with specific case scenarios. The role of palliative RT in multiple myeloma is also discussed. CONCLUSIONS: The International Lymphoma Radiation Oncology Group presents a standardized approach to the use and implementation of definitive RT in solitary plasmacytomas. The modern principles outlining the supportive role of palliative RT in multiple myeloma in an era of novel systemic therapies are also discussed. Crown
Authors: Alessandro Alghisi; Paolo Borghetti; Marta Maddalo; Aldo Maria Roccaro; Alessandra Tucci; Rosario Mazzola; Stefano Maria Magrini; Antonio Lo Casto; Marco Lorenzo Bonù; Davide Tomasini; Nadia Pasinetti; Gloria Peretto; Francesco Bertagna; Cesare Tomasi; Michela Buglione; Luca Triggiani Journal: J Cancer Res Clin Oncol Date: 2020-11-17 Impact factor: 4.553
Authors: Adnan Elhammali; Behrang Amini; Ethan B Ludmir; Jillian R Gunther; Sarah A Milgrom; Chelsea C Pinnix; Therese Andraos; Alison Yoder; Donna Weber; Robert Orlowski; Elisabet Manasanch; Krina Patel; Paolo Strati; Ranjit Nair; Hans C Lee; Sheeba Thomas; Swaminathan Iyer; Gregory Kaufmann; Naveen Garg; Bouthaina S Dabaja Journal: Haematologica Date: 2020-01-09 Impact factor: 9.941
Authors: Kafayat A Oyemade; Scott L Stafford; Morie A Gertz; Sanjay V Patel; Keith H Baratz; Lauren A Dalvin Journal: Am J Ophthalmol Case Rep Date: 2022-04-10
Authors: Jeremy G Price; Donna Niedzwiecki; Taofik Oyekunle; Murat O Arcasoy; Colin E Champ; Chris R Kelsey; Joseph K Salama; Michael J Moravan Journal: Adv Radiat Oncol Date: 2021-05-28